The confirmation of the harmful effect of CCL5 in the acute phase of stroke is supported by the correlation observed between the biomarkers of inflammation, IL-6 and TNF-α [31,32], previously determined by our research centre, which is among the first to be released during ischemia in AIS (Figure 4). This evidence concerns the gene IL6 and androgen insensitivity syndrome.